Retrospective Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine

Atherosclerotic Heart Disease With Angina Nos Clinical Trial

— RCSCD-TCM  

Official title:

Retrospective Cohort Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04026724
• Other study ID #: RCSCD-TCM
• Status: Not yet recruiting
• Start date: September 1, 2019
• Est. completion date: September 1, 2020

Study information

• Verified date: July 2019
• Source: Tianjin University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A retrospective cohort study was performed in patients with angina pectoris who were treated with oral Chinese patent medicine and Western medicine.The hospital's medical record management system was used to collect symptoms of angina pectoris, dose and frequency of nitroglycerin use, clinical biochemical test and imaging examination.To explore the clinical efficacy of Chinese patent medicine in the treatment of coronary heart disease with angina pectoris, and provide reliable data support for its clinical application.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12400
• Est. completion date: September 1, 2020
• Est. primary completion date: March 1, 2020
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 35-75 years old, gender is not limited;

2. Admission time is September 1, 2014 - September 1, 1919;

3. Patients with coronary heart disease and angina pectoris in the Department of Cardiology or Outpatient Department, the diagnosis of angina pectoris meets the diagnostic criteria of Western medicine and the standard of TCM syndrome differentiation;

4. Patients who met the criteria for drug treatment, the exposed group was treated with traditional Chinese medicine combined with Western medicine, and the non-exposed group was treated with Western medicine alone.

Exclusion Criteria:

1. Combined with other heart diseases, neurosis, menopausal syndrome, hyperthyroidism, cervical or vertebral artery type cervical spondylosis, gastro-oesophageal reflux disease or esophageal hiatus hernia may cause chest pain;

2. patients with acute myocardial infarction, heart failure, myocarditis, cardiomyopathy, severe heart valve disease, liver failure or renal failure, malignant tumors and severe metabolic diseases, as well as patients with severe symptoms and uncontrollable angina;

3. Pregnant women, lactating women or women of childbearing age who have birth requirements;

4. Mental patients, or cognitive dysfunction;

5. The investigator believes that there are other situations that are not suitable for the trial.

Related Conditions & MeSH terms

• Angina Pectoris
• Atherosclerotic Heart Disease With Angina Nos
• Coronary Artery Disease
• Coronary Disease
• Heart Diseases
• Myocardial Ischemia

Intervention

Drug:
• Chinese patent medicine
Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.

Locations

Country	Name	City	State
China	Tianjin University of Traditional Chinese Medicine	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Symptoms of angina		one year
Primary	Dosage and frequency of use of nitroglycerin		one year
Primary	Clinical biochemical indicators test		one year
Primary	Film degree exam		one year